TriangleNCT02773030 · OUTCOME
Overall Response Rate (ORR) in Cohort D and Cohort H2
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- Percentage of Participants
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Approximately on average (Cohort D: 21.14 weeks, Cohort H2: 22.11 Weeks)
What was measured
Tumor response, including progressive disease (PD) according to the IMWG Uniform Response Criteria (Kumar, 2016) for subjects who achieved partial response (PR) or better.
Analysis population: Safety Population in Cohort D and Cohort H2
Groups in this outcome
Cohort A: Treatment 1
CC220 0.30mg
Cohort A: Treatment 2
CC220 0.45mg
Cohort A: Treatment 3
CC220 0.60mg
Cohort A: Treatment 4
CC220 0.75mg
Cohort A: Treatment 5
CC220 0.90mg
Cohort A: Treatment 6
CC220 1.0mg
Cohort B: Treatment 1
CC220 0.30mg + DEX
Cohort B: Treatment 2
CC220 0.45mg + DEX
Cohort B: Treatment 3
CC220 0.60mg + DEX
Cohort B: Treatment 4
CC220 0.75mg + DEX
Cohort B: Treatment 5
CC220 0.90mg + DEX
Cohort B: Treatment 6
CC220 1.0mg + DEX
Cohort B: Treatment 7
CC220 1.1mg + DEX
Cohort B: Treatment 8
CC220 1.2mg + DEX
Cohort B: Treatment 9
CC220 1.3.mg + DEX
Cohort B: Treatment 10
CC220 1.6mg + DEX
Cohort D: Treatment 1
CC220 + DEX
Cohort E: Treatment 1
CC220 1.0mg + DARA + DEX
Cohort E: Treatment 2
CC220 1.1mg + DARA + DEX
Cohort E: Treatment 3
CC220 1.2mg + DARA + DEX
Cohort E: Treatment 4
CC220 1.3mg + DARA + DEX
Cohort E: Treatment 5
CC220 1.6mg + DARA + DEX
Cohort F: Treatment 1
CC220 1.0mg + BORT + DEX
Cohort F: Treatment 2
CC220 1.1mg + BORT + DEX
Cohort F: Treatment 3
CC220 1.3mg + BORT + DEX
Cohort F: Treatment 4
CC220 1.6mg + BORT + DEX
Cohort G: Treatment 1
CC220 1.1mg + CFZ + DEX
Cohort G: Treatment 2
CC220 1.3mg + CFZ + DEX
Cohort G: Treatment 3
CC220 1.6mg + CFZ + DEX
Cohort H1
CC220 + DEX
Cohort H2
CC220 + DEX
Cohort I
CC220 + DEX
Cohort J1: Treatment 1
CC220Vd 1.0mg + NE-ASCT
Cohort J1: Treatment 2
CC220Vd 1.6mg + NE-ASCT
Cohort K: Treatment 1
CC220 1.0mg + DARA + DEX
Cohort K: Treatment 2
CC220 1.3mg + DARA + DEX
Cohort K: Treatment 3
CC220 1.6mg + DARA + DEX
| Group | Source count |
|---|---|
| Cohort A: Treatment 1 | 0 |
| Cohort A: Treatment 2 | 0 |
| Cohort A: Treatment 3 | 0 |
| Cohort A: Treatment 4 | 0 |
| Cohort A: Treatment 5 | 0 |
| Cohort A: Treatment 6 | 0 |
| Cohort B: Treatment 1 | 0 |
| Cohort B: Treatment 2 | 0 |
| Cohort B: Treatment 3 | 0 |
| Cohort B: Treatment 4 | 0 |
| Cohort B: Treatment 5 | 0 |
| Cohort B: Treatment 6 | 0 |
| Cohort B: Treatment 7 | 0 |
| Cohort B: Treatment 8 | 0 |
| Cohort B: Treatment 9 | 0 |
| Cohort B: Treatment 10 | 0 |
| Cohort D: Treatment 1 | 107 |
| Cohort E: Treatment 1 | 0 |
| Cohort E: Treatment 2 | 0 |
| Cohort E: Treatment 3 | 0 |
| Cohort E: Treatment 4 | 0 |
| Cohort E: Treatment 5 | 0 |
| Cohort F: Treatment 1 | 0 |
| Cohort F: Treatment 2 | 0 |
| Cohort F: Treatment 3 | 0 |
| Cohort F: Treatment 4 | 0 |
| Cohort G: Treatment 1 | 0 |
| Cohort G: Treatment 2 | 0 |
| Cohort G: Treatment 3 | 0 |
| Cohort H1 | 0 |
| Cohort H2 | 5 |
| Cohort I | 0 |
| Cohort J1: Treatment 1 | 0 |
| Cohort J1: Treatment 2 | 0 |
| Cohort K: Treatment 1 | 0 |
| Cohort K: Treatment 2 | 0 |
| Cohort K: Treatment 3 | 0 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Cohort D: Treatment 1 | 26.2 | Not reported | 18.1 | 35.6 | Not reported |
| Cohort H2 | 20.0 | Not reported | 0.5 | 71.6 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG016
- lower Limit
- 18.1
- upper Limit
- 35.6
- value
- 26.2
- group Id
- OG030
- lower Limit
- 0.5
- upper Limit
- 71.6
- value
- 20.0
- denoms
- counts
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- group Id
- OG007
- value
- 0
- group Id
- OG008
- value
- 0
- group Id
- OG009
- value
- 0
- group Id
- OG010
- value
- 0
- group Id
- OG011
- value
- 0
- units
- Participants
- description
- Tumor response, including progressive disease (PD) according to the IMWG Uniform Response Criteria (Kumar, 2016) for subjects who achieved partial response (PR) or better.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- CC220 0.30mg
- id
- OG000
- title
- Cohort A: Treatment 1
- description
- CC220 0.45mg
- id
- OG001
- title
- Cohort A: Treatment 2
- description
- CC220 0.60mg
- id
- OG002
- title
- Cohort A: Treatment 3
- description
- CC220 0.75mg
- id
- OG003
- title
- Cohort A: Treatment 4
- description
- CC220 0.90mg
- id
- OG004
- title
- Cohort A: Treatment 5
- description
- CC220 1.0mg
- id
- OG005
- title
- Cohort A: Treatment 6
- description
- CC220 0.30mg + DEX
- id
- OG006
- title
- Cohort B: Treatment 1
- description
- CC220 0.45mg + DEX
- id
- OG007
- title
- Cohort B: Treatment 2
- description
- CC220 0.60mg + DEX
- id
- OG008
- title
- Cohort B: Treatment 3
- description
- CC220 0.75mg + DEX
- id
- OG009
- title
- Cohort B: Treatment 4
- description
- CC220 0.90mg + DEX
- id
- OG010
- title
- Cohort B: Treatment 5
- description
- CC220 1.0mg + DEX
- id
- OG011
- title
- Cohort B: Treatment 6
- param Type
- NUMBER
- population Description
- Safety Population in Cohort D and Cohort H2
- reporting Status
- POSTED
- time Frame
- Approximately on average (Cohort D: 21.14 weeks, Cohort H2: 22.11 Weeks)
- title
- Overall Response Rate (ORR) in Cohort D and Cohort H2
- type
- PRIMARY
- unit Of Measure
- Percentage of Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice